A current overview of corticosteroid use in active ulcerative colitis

References

• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–670.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, D’Arienzo A, Rizzello F, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol. 2005;39:291–297.
   PubMed Web of Science ®Google Scholar
• Biancone L, Gionchetti P, Blanco Gdel V, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Digestive Liver Dis. 2007;39:329–337.
   Web of Science ®Google Scholar
• Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther. 2007;26:21–29.
   PubMed Web of Science ®Google Scholar
• Zhao H, Li N, Ren Y, et al. Efficacy and safety of beclomethasone dipropionate versus 5-aminosalicylic acid in the treatment of ulcerative colitis: a systematic review and meta-analysis. PLoS One. 2016;11:a0160500.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J. 1962;2:1708–1711.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Longmore AJ, Newell AC, et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut. 1960;1:217–222.
   PubMed Web of Science ®Google Scholar
• Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J. 1962;2:441–443.
   PubMedGoogle Scholar
• Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther. 2003;17:1471–1480.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Manguso F, Zibellini M, et al. Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study. Am J Gastroenterol. 2015;110:708–715.
   PubMed Web of Science ®Google Scholar
• Manguso F, Bennato R, Lombardi G, et al. Efficacy and safety of oral beclomethasone dipropionate in ulcerative colitis: a systematic review and meta-analysis. PLoS One. 2016;11:e0166455.
   PubMed Web of Science ®Google Scholar
• Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;10:CD007698–CD007698. doi:10.1002/14651858.CD007698.pub2.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis—results from the CORE I study. Gastroenterology. 2012;143:1218–1226.
   PubMed Web of Science ®Google Scholar
• Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63:433–441.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Cohen RDSandborn WJ, Budesonide multimatrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: a randomised, placebo-controlled trial. J Crohns Colitis. 2017;11(7):785–791.
   PubMed Web of Science ®Google Scholar
• Sherlock ME, MacDonald JK, Griffiths AM, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Systematic Rev. 2015;10:CD007698. doi:10.1002/14651858.CD007698.pub3.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Abreu M, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940–987.
   PubMed Web of Science ®Google Scholar
• Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of cortico- steroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.
   PubMed Web of Science ®Google Scholar
• Jain S, Kedia S, Bopanna S, et al. Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. Intest Res. 2018;16(1):69–74.
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845.
   PubMed Web of Science ®Google Scholar
• Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Part 1: short-term prognosis. Gut. 1963;4:300–308.
   Web of Science ®Google Scholar
• Turner D, Cm W, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.
   PubMed Web of Science ®Google Scholar
• Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067–1070.
   PubMed Web of Science ®Google Scholar
• Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a ran- domized, double-blind trial. Am J Gastroenterol. 2007;102:601–608.
   PubMed Web of Science ®Google Scholar
• Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990;12:40–41.
   PubMed Web of Science ®Google Scholar
• Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–110.
   PubMed Web of Science ®Google Scholar
• Meyers S, Lerer PK, Feuer EJ, et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis: results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol. 1987;9:50–54.
   PubMed Web of Science ®Google Scholar
• JäRnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985;89:1005–1013.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE, Ritchie JK, Hilder W, et al. Assessment of severity in colitis: a preliminary study. Gut. 1975;16:579–584.
   PubMed Web of Science ®Google Scholar
• Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–910.
   PubMed Web of Science ®Google Scholar
• Travis S. How do you avoid and treat steroid side effects? Inflamm Bowel Dis. 2008;14:214–215.
   Web of Science ®Google Scholar
• Rizzello F, Mazza M, Salice M, et al. The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. Expert Opin Drug Saf. 2018;17(9):963–969.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, D’Arienzo A, Rizzello F, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol. 2005;39:291–297.
   PubMed Web of Science ®Google Scholar
• Biancone L, Gionchetti P, Del Vecchio Blanco G, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liv Dis. 2007;39:329–337.
   Web of Science ®Google Scholar
• Rizzello F, Gionchetti P, Galeazzi R, et al. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv Ther. 2001;18:261–271.
   PubMed Web of Science ®Google Scholar
• Rizzello F, Gionchetti P, D’Arienzo A, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2002;16:1109–1116.
   PubMed Web of Science ®Google Scholar
• Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther. 2003;17:1471–1480.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Nikolopoulos GK, Lytras T, et al. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: systematic review and network meta-analysis. Br J Clin Pharmacol. 2018;84:239–251.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Leung S, Lix LM, et al. Persistence with immunomodulator monotherapy use and incidence of therapeutic ineffectiveness among users of immunomodulator monotherapy in IBD. Am J Gastroenterol. 2018;113(8):1206–1216.
   PubMed Web of Science ®Google Scholar
• Selinger CP, Parkes GC, Bassi A, et al. A multi-center audit of excess steroid use in 1176 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(10):964–973.
   PubMed Web of Science ®Google Scholar
• Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24(2):319–330.
   PubMed Web of Science ®Google Scholar